Datapoint: Gilead Scores Expanded Hep B Nod for Vemlidy

The FDA last week expanded Gilead Sciences’ chronic hepatitis B virus (HBV) drug Vemlidy’s label to include pediatric patients 12 and older with compensated liver disease. The drug was first approved in 2016. As of November 2022, 91% of insured lives have covered or better access to Vemlidy, with 25% of lives having preferred access to the drug without utilization management restrictions.

SOURCE: MMIT Analytics, as of 11/7/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today